Thu, October 29, 2020

Michael Schmitz Maintained (BPMC) at Strong Buy with Increased Target to $120 on, Oct 29th, 2020

Michael Schmitz of Guggenheim, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $106 to $120 on, Oct 29th, 2020.

Michael has made no other calls on BPMC in the last 4 months.



There are 3 other peers that have a rating on BPMC. Out of the 3 peers that are also analyzing BPMC, 0 agree with Michael's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Michael


  • Dane Leone of "Raymond James" Maintained at Strong Buy with Increased Target to $122 on, Friday, October 16th, 2020
  • Andrew Berens of "Morgan Stanley" Maintained at Buy with Increased Target to $100 on, Tuesday, October 13th, 2020
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $110 on, Wednesday, July 15th, 2020